Literature DB >> 20887718

Pro-inflammatory and atherogenic circulating factors in non-alcoholic fatty liver disease associated to metabolic syndrome.

Diego Lucero1, Valeria Zago, Graciela I López, Mabel Graffigna, Hugo Fainboim, Verónica Miksztowicz, Tomás Meroño, Susana Belli, Oscar Levalle, Regina Wikinski, Fernando Brites, Gabriela Berg, Laura Schreier.   

Abstract

BACKGROUND: It is not elucidated if liver fat deposits associated to metabolic syndrome (MS) aggravate the atherogenic state. We evaluated, in MS patients, if the presence of non-alcoholic hepatic steatosis (HS) determines differences in inflammatory markers and VLDL characteristics.
METHODS: Seventy-five patients with MS were divided into 2 groups depending on the presence or absence of HS, assessed by ultrasound. Lipid profile, free fatty acids (FFA), VLDL composition, adiponectin, tumor necrosis factor-alpha (TNF-α), high sensitivity C-reactive protein (hs-CRP), and soluble adhesion molecules (sVCAM-1 and sICAM-1) were measured.
RESULTS: HS patients presented increased triglycerides levels, HOMA-IR and FFA. Patients with HS showed a reduction in adiponectin (p = 0.04) and increase in hs-CRP (p = 0.02), independently of insulin-resistance (IR). FFA correlated positively with TNF-α (p = 0.04) and inversely with adiponectin (p = 0.01). hs-CRP correlated with all inflammatory markers, independently of IR: TNF-α (r = 0.34, p = 0.02), sVCAM-1 (r = 0.29 p = 0.03), sICAM-1 (r = 0.56, p = 0.01), adiponectin (r = -0.34, p = 0.04). HS patients presented higher VLDL mass and number of particles. Adiponectin correlated with VLDL cholesterol content (r = -0.47, p = 0.04), independently of IR. VLDL, once secreted, would suffer from changes, becoming more atherogenic.
CONCLUSIONS: Simple HS would play an important role increasing cardiovascular risk, independently of IR. hs-CRP may represent a useful biomarker of this condition.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20887718     DOI: 10.1016/j.cca.2010.09.025

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  10 in total

1.  Atherogenic dyslipidemia and cardiovascular risk in children with nonalcoholic fatty liver disease.

Authors:  Naim Alkhouri; Christine Carter-Kent; Michael Elias; Ariel E Feldstein
Journal:  Clin Lipidol       Date:  2011-06-01

Review 2.  What does irritable bowel syndrome share with non-alcoholic fatty liver disease?

Authors:  Antonella Scalera; Matteo Nicola Dario Di Minno; Giovanni Tarantino
Journal:  World J Gastroenterol       Date:  2013-09-07       Impact factor: 5.742

3.  Treating NAFLD in OLETF rats with vigorous-intensity interval exercise training.

Authors:  Melissa A Linden; Justin A Fletcher; E Matthew Morris; Grace M Meers; M Harold Laughlin; Frank W Booth; James R Sowers; Jamal A Ibdah; John P Thyfault; R Scott Rector
Journal:  Med Sci Sports Exerc       Date:  2015-03       Impact factor: 5.411

Review 4.  Role of cytokines and chemokines in non-alcoholic fatty liver disease.

Authors:  Vincent Braunersreuther; Giorgio Luciano Viviani; François Mach; Fabrizio Montecucco
Journal:  World J Gastroenterol       Date:  2012-02-28       Impact factor: 5.742

5.  Computed tomography scans in the evaluation of fatty liver disease in a population based study: the multi-ethnic study of atherosclerosis.

Authors:  Irfan Zeb; Dong Li; Khurram Nasir; Ronit Katz; Vahid N Larijani; Matthew J Budoff
Journal:  Acad Radiol       Date:  2012-04-21       Impact factor: 3.173

6.  Increased H-FABP concentrations in nonalcoholic fatty liver disease. Possible marker for subclinical myocardial damage and subclinical atherosclerosis.

Authors:  O Başar; E Akbal; S Köklü; Y Tuna; E Koçak; N Başar; D Tok; H Erbiş; M Senes
Journal:  Herz       Date:  2013-01-18       Impact factor: 1.443

Review 7.  Cardiovascular dysfunction in obesity and new diagnostic imaging techniques: the role of noninvasive image methods.

Authors:  José Augusto A Barbosa; Alexandre B Rodrigues; Cleonice Carvalho C Mota; Márcia M Barbosa; Ana C Simões e Silva
Journal:  Vasc Health Risk Manag       Date:  2011-05-10

8.  Causes of Thickening of Carotid Intima-Media Thickness in Patients With Alcoholic Liver Disease: A Prospective Observational Study.

Authors:  Bao-Ge Qu; Hui Wang; Yuan-Xun Liu; Yi-Guo Jia; Ji-Liang Su; Zhong-Dong Wang; Ya-Fei Wang; Xing-Hai Han; Jin-Dun Pan
Journal:  Medicine (Baltimore)       Date:  2015-07       Impact factor: 1.889

9.  A randomised placebo controlled trial of VSL#3® probiotic on biomarkers of cardiovascular risk and liver injury in non-alcoholic fatty liver disease.

Authors:  Pui Lin Chong; David Laight; Richard J Aspinall; Antony Higginson; Michael H Cummings
Journal:  BMC Gastroenterol       Date:  2021-04-01       Impact factor: 3.067

10.  Empagliflozin activates Sestrin2-mediated AMPK/mTOR pathway and ameliorates lipid accumulation in obesity-related nonalcoholic fatty liver disease.

Authors:  Yuting Ma; Guangdong Zhang; Zenggguang Kuang; Qian Xu; Tongtong Ye; Xue Li; Na Qu; Fang Han; Chengxia Kan; Xiaodong Sun
Journal:  Front Pharmacol       Date:  2022-09-05       Impact factor: 5.988

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.